{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:56:41Z","timestamp":1791946601679,"version":"4.3.4"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2019.03154","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T02:37:14Z","timestamp":1580351834000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Clinical Development of New TB Vaccines: Recent Advances and Next Steps"],"prefix":"10.3389","volume":"10","author":[{"given":"Mark","family":"Hatherill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Hawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/infdis\/jir240","article-title":"Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?","volume":"204","author":"Aaby","year":"2011","journal-title":"J. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17370","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis.","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technol. Assess."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16085","article-title":"Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis.","volume":"8","author":"Aguilo","year":"2017","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/230240bc-bcf3-46b2-9b21-2e6e584f7333","article-title":"Collaborative group for meta-analysis of individual patient data in, multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med."},{"key":"B6","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. this official statement of the american thoracic society was adopted by the ats board of directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.","volume":"161","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","article-title":"Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.","volume":"5","author":"Andrews","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.","volume":"54","author":"Andrews","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1001\/jama.291.17.2086","article-title":"Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study.","volume":"291","author":"Aronson","year":"2004","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients.","volume":"18","author":"Aung","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B12","first-page":"1171","article-title":"Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil.","volume":"9","author":"Barreto","year":"2005","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1016\/j.vaccine.2011.05.023","article-title":"Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial.","volume":"29","author":"Barreto","year":"2011","journal-title":"Vaccine"},{"key":"B14","article-title":"Revisiting the timetable of tuberculosis.","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(02)08353-8","article-title":"BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.","volume":"359","author":"Black","year":"2002","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5588\/ijtld.18.0283","article-title":"Temporal trends in the prevalence of Mycobacterium tuberculosis infection in South African adolescents.","volume":"23","author":"Bunyasi","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009501","article-title":"PET\/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.","volume":"6","author":"Chen","year":"2014","journal-title":"Sci. Trans. Med."},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis.","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","article-title":"Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in South African adults.","volume":"188","author":"Day","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/trstmh\/trz049","article-title":"Age-specific prevalence of TB infection among household contacts of pulmonary TB: is it time for TB preventive therapy?","volume":"113","author":"Dolla","year":"2019","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tube.2015.02.036","article-title":"Innovative clinical trial designs to rationalize TB vaccine development.","volume":"95","author":"Ellis","year":"2015","journal-title":"Tuberculosis"},{"key":"B22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/0035-9203(88)90003-X","article-title":"Leprosy in Malawi. 2. Background, design and prospects of the Karonga prevention trial, a leprosy vaccine trial in northern Malawi.","volume":"82","author":"Fine","year":"1988","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/infdis\/jir760","article-title":"Non-specific effects of BCG?","volume":"205","author":"Fine","year":"2012","journal-title":"J. Infect. Dis."},{"key":"B24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(14)71085-0","article-title":"Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study.","volume":"15","author":"Gao","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"B25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/14760584.2016.1178067","article-title":"Design of tuberculosis vaccine trials under financial constraints.","volume":"15","author":"Garcia-Basteiro","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study.","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.","volume":"371","author":"Gillespie","year":"2014","journal-title":"New Eng. J. Med."},{"key":"B29","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin.","volume":"115","author":"Grode","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B30","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","article-title":"Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines.","volume":"12","author":"Harris","year":"2016","journal-title":"Hum. Vacc. Immunother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1016\/S2214-109X(18)30452-2","article-title":"Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.","volume":"7","author":"Harris","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"B32","article-title":"RG. The potential epidemiological impact of new TB vaccines","author":"Harris","year":"2018","journal-title":"Proceedings of the TB Science at the 49th Union World Conference on Lung Health"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.1.20240","article-title":"Temporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis.","volume":"18","author":"Hermans","year":"2015","journal-title":"J. Int. AIDS Soc."},{"key":"B34","article-title":"Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants.","volume":"12","author":"Hesseling","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2471\/BLT.08.055657","article-title":"Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants.","volume":"87","author":"Hesseling","year":"2009","journal-title":"Bull. World Health Organ."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med."},{"key":"B37","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/infdis\/jiw467","article-title":"Induction of an immune-protective T-Cell repertoire with diverse genetic coverage by a novel Viral-vectored Tuberculosis vaccine in humans.","volume":"214","author":"Jeyanathan","year":"2016","journal-title":"J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.","volume":"371","author":"Jindani","year":"2014","journal-title":"New Eng. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.","volume":"111","author":"Knight","year":"2014","journal-title":"Proc. Natl. Acad. Sci U.S.A."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013120","article-title":"Long-term safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.","volume":"97","author":"Kumarasamy","year":"2018","journal-title":"Medicine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002459","article-title":"Controlled safety, and immunogenicity trial of the M72\/AS01 candidate tuberculosis vaccine in HIV-Positive Indian adults.","volume":"95","author":"Kumarasamy","year":"2016","journal-title":"Medicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/QAD.0b013e32832d3b6d","article-title":"Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.","volume":"23","author":"Lawn","year":"2009","journal-title":"AIDS"},{"key":"B43","first-page":"717","article-title":"Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.","volume":"5","author":"Leung","year":"2001","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/s41591-019-0441-3","article-title":"IFN-gamma-independent immune markers of Mycobacterium tuberculosis exposure.","volume":"25","author":"Lu","year":"2019","journal-title":"Nat. Med."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017984","article-title":"The Tuberculin skin test versus QuantiFERON TB Gold (R) in predicting tuberculosis disease in an adolescent cohort study in South Africa.","volume":"6","author":"Mahomed","year":"","journal-title":"PLoS One"},{"key":"B46","first-page":"331","article-title":"Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa.","volume":"15","author":"Mahomed","year":"","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B47","first-page":"310","article-title":"Comparison of Mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection.","volume":"10","author":"Mahomed","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials.","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ije\/dyx141","article-title":"The duration of protection of school-aged BCG vaccination in England: a population-based case-control study.","volume":"47","author":"Mangtani","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21390","article-title":"Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guerin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.","volume":"21","author":"Mangtani","year":"2017","journal-title":"Health Technol. Assess."},{"key":"B51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/trstmh\/trw006","article-title":"Drug-resistant TB: deadly, costly and in need of a vaccine.","volume":"110","author":"Manjelievskaia","year":"2016","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/cid\/ciu186","article-title":"The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study.","volume":"58","author":"Marx","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B53","doi-asserted-by":"crossref","first-page":"A20","DOI":"10.1016\/j.vaccine.2016.10.031","article-title":"European strategy for vaccine development against infectious diseases.","volume":"35","author":"Matthiessen","year":"2017","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis.","volume":"371","author":"Merle","year":"2014","journal-title":"New Eng. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4314\/ahs.v15i3.20","article-title":"Prevalence and risk factors of latent Tuberculosis among adolescents in rural Eastern Uganda.","volume":"15","author":"Mumpe-Mwanja","year":"2015","journal-title":"Afr. Health Sci."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4314-7","article-title":"Estimating the annual risk of infection with Mycobacterium tuberculosis among adolescents in Western Kenya in preparation for TB vaccine trials.","volume":"19","author":"Nduba","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection.","volume":"9","author":"Nell","year":"2014","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/ciz034","article-title":"Diagnostic accuracy of ESAT-6 free IGRA compared to QuantiFERON-TB Gold In-tube.","volume":"69","author":"Nemes","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.","volume":"379","author":"Nemes","year":"","journal-title":"New Eng. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/COH.0000000000000496","article-title":"Prospects for a vaccine to prevent HIV-related tuberculosis.","volume":"13","author":"Nemes","year":"","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant bacille Calmette-Guerin vaccine VPM1002: ready for clinical efficacy testing.","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front. Immun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis.","volume":"380","author":"Nunn","year":"2019","journal-title":"New Eng. J Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting.","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002781","article-title":"Discovery and validation of a prognostic proteomic signature for tuberculosis progression: a prospective cohort study.","volume":"16","author":"Penn-Nicholson","year":"2019","journal-title":"PLoS Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0140-6736(92)90794-4","article-title":"Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.","volume":"339","author":"Ponnighaus","year":"1992","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtbi.2019.02.020","article-title":"Evaluating vaccination strategies for tuberculosis in endemic and non-endemic settings.","volume":"469","author":"Renardy","year":"2019","journal-title":"J. Theor. Biol."},{"key":"B68","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial.","volume":"366","author":"Rodrigues","year":"2005","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis.","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"B70","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","article-title":"WHO preferred product characteristics for new vaccines against tuberculosis.","volume":"18","author":"Schrager","year":"2018","journal-title":"Lancet"},{"key":"B71","article-title":"Human immunology of tuberculosis.","volume":"4","author":"Scriba","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/infdis\/jiz285","article-title":"Nontuberculous mycobacteria and heterologous immunity to tuberculosis.","volume":"220","author":"Shah","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03514-1","article-title":"Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial.","volume":"7","author":"Sharma","year":"2017","journal-title":"Sci. Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Tuberculosis trials consortium, and i. the aids clinical trials group for the prevent Tb trial are listed in the supplement, three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"B76","first-page":"200","article-title":"Does the efficacy of BCG decline with time since vaccination?","volume":"2","author":"Sterne","year":"1998","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1164\/rccm.201802-0366OC","article-title":"Dose optimization of H56:IC31 Vaccine for TB endemic populations: a double-blind, placebo-controlled, dose-selection trial.","volume":"199","author":"Suliman","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1164\/rccm.201711-2340OC","article-title":"Four-gene pan-african blood signature predicts progression to Tuberculosis.","volume":"197","author":"Suliman","year":"","journal-title":"Am. J. Respirat. Crit. Care Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-Related Tuberculosis.","volume":"380","author":"Swindells","year":"2019","journal-title":"Newx Eng. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis.","volume":"381","author":"Tait","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/513642","article-title":"Disseminated bacille Calmette-Guerin disease after vaccination: case report and review.","volume":"24","author":"Talbot","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"B82","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1097\/QAD.0000000000000343","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I\/II, randomized trial.","volume":"28","author":"Thacher","year":"2014","journal-title":"AIDS"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176784","article-title":"Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models.","volume":"12","author":"Tkachuk","year":"2017","journal-title":"PLoS One"},{"key":"B86","first-page":"502","article-title":"Disseminated tuberculoid lesions in infants following BCG vaccination.","volume":"127","author":"Trevenen","year":"1982","journal-title":"Can. Med. Assoc. J."},{"key":"B87","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new end TB strategy.","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis.","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"New Eng. J. Med."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175215","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901.","volume":"12","author":"von Reyn","year":"2017","journal-title":"PLoS One"},{"key":"B90","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13588.1","article-title":"Progress and challenges in TB vaccine development.","volume":"7","author":"Voss","year":"2018","journal-title":"F1000Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.vaccine.2009.12.083","article-title":"The second Geneva Consensus: recommendations for novel live TB vaccines.","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"B93","first-page":"255","article-title":"Advancing host-directed therapy for tuberculosis.","volume":"15","author":"Wallis","year":"2015","journal-title":"Nat. Rev."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.3779","article-title":"Assessment of validity of a Blood-Based 3-Gene signature score for progression and diagnosis of Tuberculosis, disease severity, and treatment response.","volume":"1","author":"Warsinske","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"B95","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3892\/br.2016.624","article-title":"Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"4","author":"Weng","year":"2016","journal-title":"Biomed. Rep."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-211147","article-title":"Stratification by interferon-gamma release assay level predicts risk of incident TB.","author":"Winje","year":"2018","journal-title":"Thorax"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","article-title":"BCG vaccine: WHO position paper, February 2018 - Recommendations.","volume":"36","year":"","journal-title":"Vaccine"},{"key":"B98","year":"","journal-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management."},{"key":"B99","year":"","journal-title":"World Health Organization Global Tuberculosis Report."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023826","article-title":"Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"key":"B101","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/S0140-6736(15)01316-1","article-title":"A blood RNA signature for tuberculosis disease risk: a prospective cohort study.","volume":"387","author":"Zak","year":"2016","journal-title":"Lancet"},{"key":"B102","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis.","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann. Int. Med."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG World Atlas: a database of global BCG vaccination policies and practices.","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.03154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T02:37:22Z","timestamp":1580351842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.03154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":103,"alternative-id":["10.3389\/fmicb.2019.03154"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2019.03154","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"article-number":"3154"}}